Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.

Nat Commun · 2026 · PMC13439560 · PMID 42151180

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Similarly, survival analysis indicated that all three treatment regimens significantly prolonged survival compared with controls, with a numerical trend toward greater survival benefits in the HAIC plus anti-PD-L1 group relative to both systemic treatment groups (Supplementary Fig. 18K ).

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.